COMMUNIQUÉS West-GlobeNewswire

European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
29/07/2019
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated [...]
Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
29/07/2019
CRANBURY, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019 at 8:30 a.m. ET to [...]
Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
29/07/2019
Extends interest-only period and time to access additional funding NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel [...]
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%
29/07/2019
Potential First-in-Class Treatment VANCOUVER, British Columbia, July 29, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical [...]
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
29/07/2019
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Global Phase 3 [...]
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019
29/07/2019
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]
Novo Nordisk A/S – Share repurchase programme
29/07/2019
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 29 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European [...]
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-802 for the treatment of MPI-CDG
29/07/2019
ROCKVILLE, Md., July 29, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in [...]
Union Terminal’s Modern Technology Enables a World-Class Experience for Cincinnati Museum Center Visitors
29/07/2019
CINCINNATI, July 29, 2019 (GLOBE NEWSWIRE) -- “Modernization” is not a new concept for 1933-Cincinnati-icon, Union Terminal. From the Art Deco architecture characteristic of the 1920s and -30s to the gravity-defying [...]
Arrayit Corporation Announces Global Expansion of Finger Stick Health and Wellness Testing Services
29/07/2019
Food Sensitivity Testing Now Available in the Philippines Sunnyvale, July 29, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces expansion of its [...]
Online Muslim Mental Health company TherapyLine that aims to Normalize Mental Health services in the Muslim world launches in the UK, Australia and New Zealand this week.
29/07/2019
LONDON, July 29, 2019 (GLOBE NEWSWIRE) -- TherapyLine, the online mobile mental health company for Muslims, launches in three new markets today, UK, Australia and New Zealand, as part of a larger plan to provide [...]
Share buy-back week 30/2019
29/07/2019
Announcement 29 July 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
Zealand Pharma announces change in corporate management
29/07/2019
Company announcement – No. 24 / 2019 Zealand Pharma announces change in corporate management Copenhagen, Denmark, July 29, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) announces that Andrew [...]
GENFIT: FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
29/07/2019
FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), July 29, 2019 – GENFIT (Nasdaq and Euronext: GNFT) , a late- [...]
GENFIT : La FDA et l’EMA accordent la désignation d’Orphan Drug à elafibranor pour le traitement de la Cholangite Biliaire Primitive (PBC)
29/07/2019
La FDA et l’EMA accordent la désignation d’Orphan Drug à elafibranor pour le traitement de la Cholangite Biliaire Primitive (PBC) Lille (France), Cambridge (Massachusetts, États-Unis), le 29 juillet 2019 – GENFIT ( [...]
Sanofi delivered solid growth in Q2 2019
29/07/2019
Paris, July 29, 2019 Sanofi delivered solid growth in Q2 2019 Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.5% +3.9% €17,019m +5.9% +4.1% IFRS net income reported -€87m - [...]
Sanofi affiche une croissance solide au deuxième trimestre 2019
29/07/2019
Paris, le 29 juillet 2019 Sanofi affiche une croissance solide au deuxième trimestre 2019 T2 2019 Variation Variation à TCC S1 2019 Variation Variation à TCC Chiffre d’affaires net IFRS publié €8 628m +5,5% +3,9% €17 [...]
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
29/07/2019
PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will be presented in [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/07/2019
WALTHAM, Mass. and CRESTWOOD, Ky., July 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]

Pages